

Ref. No:	1687
Date:	17/04/25
Subject:	Multiple Myeloma

## REQUEST

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

Q2. Of the multiple myeloma patients treated over the past 6 months, how many were treated with the following:

1. Any other systemic anti-cancer therapy
2. Belantamab Mafodotin [Blenrep]
3. Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone
4. Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone
5. Bortezomib [Velcade] monotherapy or with dexamethasone
6. Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
7. Bortezomib, thalidomide and dexamethasone [VTD]
8. Carfilzomib [Kyprolis] and dexamethasone
9. Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone
10. Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone
11. Daratumumab [Darzalex] monotherapy
12. Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
13. Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
14. Elranatamab
15. Idecabtagene vicleucel [Abecma]
16. Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
17. Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)
18. Lenalidomide [Revlimid] and dexamethasone

19. Lenalidomide [Revlimid] monotherapy
20. Panobinostat in combination with Bortezomib and Dezamethasone
21. Pomalidomide [Imnovid] and dexamethasone
22. Selinexor and dexamethasone
23. Selinexor, Bortezomib [Velcade] and dexamethasone
24. Talquetamab
25. Teclistamab [Tecvayli]

## RESPONSE

Over the past 6 months (01/10/24 – 31/03/24), 37 adult multiple myeloma [MM] patients have been treated at MWL. Over the same time period, <5 adult multiple myeloma [MM] patients were referred and treated at Clatterbridge Cancer Centre.

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.